WHO vaccine-preventable diseases: monitoring system. 2017 global summary

Last updated 15-July-2017 (data as of 11-July-2017)
Next overall update Fall-2017
EPI mother and child logo         
Select a country

Development status: Developing GNI / capita (US$): 12'0501 Infant (under 12 months) mortality rate: 152
GDP / capita (US$): 22'1921 Child (under 5 years) mortality rate: 172

Population data in thousands3

  2016  2015  2014  2013  2012  2000  1990  1980 
Total population 4'034  3'969  3'904  3'838  3'773  3'030  2'471  1'979 
Births 79  79  79  78  78  71  65  61 
Surviving infants 78  78  77  77  77  70  63  59 
Pop. less than 5 years 388  386  384  381  378  342  310  288 
Pop. less than 15 years 1'115  1'106  1'098  1'090  1'081  969  887  809 
Female 15-49 years 1'037  1'024  1'010  996  981  798  627  465 

Number of reported cases

(Click for retrospective incidence data for Panama)
Diphtheria
ChartChart
 
Japanese encephalitis
 
Measles
ChartChart ChartChart
  1'891  2'096 
Mumps
ChartChart
  110  132  108  165  134  303 
Pertussis
ChartChart
  19  42  47  66  19  641 
Polio*
ChartChart
 
Rubella
ChartChart
  580 
Rubella (CRS)
ChartChart
 
Tetanus (neonatal)
ChartChart
  19 
Tetanus (total)**
ChartChart
  10  10  31 
Yellow fever
ChartChart
 
* Polio refers to all polio cases (indigenous or imported), including polio cases caused by vaccine derived polio viruses (VDPV). For disaggregated data please click on this hyperlink: https://extranet.who.int/polis/public/CaseCount.aspx
it does not include cases of vaccine-associated paralytic polio (VAPP) and cases of non polio acute flaccid paralysis [AFP]).
** Neonatal Tetanus and Total Tetanus cases equality may be the result from a lack of non-Neonatal Tetanus surveillance system.

Percentage target population vaccinated by antigen

Hovering over an antigen reveals its fuller definition
  Most recent coverage survey4  

Official country estimates5

  (Click for retrospective coverage estimates data for Panama)
Vaccine year result method % card seen                                                
BCG          99*  99*  99  94  99*  99*  97  99* 
DTP1          99*  96  96  93  99  99* 
DTP3          86  73  80  80  85  98  86  70 
DTP4          87  91  80 
IPV1          99*  80  40 
HepB_BD          84  85  84  79  87 
HepB3          86  73  80  80  85 
Hib3          86  73  80  80  85 
JapEnc         
MCV1          99*  99*  90  92  98  97  73  71 
MCV2          99*  92  90  68  72  88 
MenA         
PCV1          99*  98  98  92  99* 
PCV2          94  92  91  88  99* 
PCV3          83  82  47 
Pol3          86  72  80  80  87  99  86  70 
Rota1          99*  98  96  93  99* 
RotaC          92  87  87  87  92 
RCV1          99*  99*  90  92  98 
TT2plus          57  66  87  99*  99*  32  16 
PAB         
VAD1          45  47  30  44  82 
YFV          81  60  69  52  99* 
* indicates the country reported above 100% coverage.

  Next update: Mid-July 2018

WHO-UNICEF estimates6

  (Click for full retrospective WHO-UNICEF coverage estimates data for Panama)
BCG
ChartChart
  99  99  99  95  98  99  97  99 
DTP1
ChartChart
  96  96  96  93  99  99  95  72 
DTP3
ChartChart
  73  73  80  80  85  98  86  47 
HepB3
ChartChart
  73  73  80  80  85 
HepB_BD
ChartChart
  84  85  84  79  87 
Hib3
ChartChart
  73  73  80  80  85 
MCV1
ChartChart
  90  90  90  92  98  97  73  71 
MCV2
ChartChart
  92  92  90  68  72  88 
PCV3
ChartChart
  83  82  75  68  62 
Pol3
ChartChart
  72  72  80  81  87  99  86  70 
RCV1
ChartChart
  90  90  90  92  98  97 
RotaC
ChartChart
  92  87  87  87  92 
YFV
ChartChart
 

Click for WHO-UNICEF coverage estimates data for PAB time series.

Number of districts in the country 78  Proportion of
districts reporting
DTP3 coverage:
% of coverage reports received at national
level vs number of reports expected
100 
   
/
|
|
\
Greater or equal to 90% 55
From 80 to 89% 21
From 50 to 79% 24
Less than 50% 0
Proportion of districts
not reporting DTP3 coverage
0
DTP3 reported coverageDTP3 reported coverage

Immunization Schedule (2016 or latest available)

Hovering over an antigen reveals its fuller definition
Vaccine Schedule Entire country Comment
BCG birth; Yes
DTaPHibHepIPV 2, 4, 6 months; Yes
DTwP 4 years; Yes
DTwPHep 18 months; Yes
HepA_Adult < 19 years; Yes risk groups
HepA_Pediatric 12, 18 months; Yes
HepB_Adult 1st contact; +1, +6 months; Yes risk groups
HepB_Pediatric birth; Yes
HPV 10 years; +6 months; Yes
Influenza_Adult > 60 years; Yes and adults with chronic diseases, pregnant women, health care workers and other risk groups
Influenza_Pediatric 6-23, 24-59 months; Yes and children with chronic diseases
IPV 18 months; 4 years; Yes
MenACWY < 1 year; Yes outbreak resopnse
MMR 12, 18 months; Yes
MR 19 years; Yes CBAW, Postpartum and general population not vaccinated with MMR before.
Pneumo_conj 2, 4, 12 months; Yes and risk groups
Pneumo_ps > 60 years; Yes and risk groups above 2 years ol
Rabies Yes Post exposure
Rotavirus 2, 4 months; Yes
Td 1st contact; +4 weeks; +6-12 months; Yes CBAW, PW, Postpartum
Tdap 10 years; Yes pregant women and risk groups
Varicella 15 months; 4 years; Yes and in case of outbreaks
VitaminA 1 year; 2 years (x2); Yes and postpartum
YF 15 months; No high risk areas

Immunizaton indicators

Indicator Expected answer 2016  2015  2014  2013  2012  2011  2010 

Planning and management

Has the country a Multi-Year Plan (MYP) for immunization? Yes/No/NR Yes  Yes  Yes  Yes  Yes  No  No 
What years does the MYP cover? number   2'019  2'019    2'015    2'010 
Nº of districts with microplans that include activities to raise immunization coverage number 78  79  72  79  14  17  76 

System performance

Total Nº districts in country number 78  79  79  79  77  77  76 
Nº districts with DTP3 coverage >=80% number 59  25  49  54  67  58  76 
% of districts with DTP3 coverage >=80% From 0 to 100% 76  32  62  68  87  75  100 
Nº districts with measles (MCV1) coverage >=95% number 35  24  31  34  39  56  63 
% of districts with MCV1 coverage >=95% From 0 to 100% 45  30  39  43  51  73  83 

Safety

Has the country a vaccine adverse events review committee? Yes/No/NR/ND Yes  Yes  Yes  No  Yes  No  Yes 
Is there a national system to monitor adverse events following immunization (AEFI)? Yes/No/NR Yes  Yes  Yes  Yes  Yes  Yes  Yes 

Finance

% of Immunization expenditure financed, using Government funds? From 0 to 100% 100  100  87  87  100  99  99 

National Immunization Advisory Mechanism

Has the country a standing technical advisory group on immunization (NITAG)? Yes/No/NR Yes  Yes  Yes  Yes  Yes  Yes  Yes 

Sources

 1  "The 2017 World Bank Development Indicators Online", GDP per capita is PPP adjusted.
 2  World Health Statistics 2016, data for 2015
 3  "United Nations, Population Division. The World Population Prospects - the 2017 revision". New York, 2017.
 4  UNICEF/WHO survey database
 5  If no official estimate is available, the administrative coverage is reported. '*' indicates coverage over 99.5%.
 6  WHO-UNICEF estimates.